TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32939556

Group type: EXPERIMENTAL
Intervention: Glycine intake (5-100 mg·kg‐1·d‐1) during late gestation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glycine intake (5-100 mg·kg‐1·d‐1) during midgestation
Number of subjects: 17
Study: 32246748

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intra-oral placebo appliance
Number of subjects: 64
Study: 34226226

Group type: EXPERIMENTAL
Intervention: Oral furosemide 80 mg/day (adjusted to 160 mg/day if urine volume < 400 mL/day after 2 weeks)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 560
Study: 34348606

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard evidence-based therapies
Number of subjects: 0
Study: 32715937

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) classifier used to predict treatment effect perception based on primary endpoints and judges' evaluations.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nine primary endpoints relating to skin pores assessed by a specific image analysis algorithm.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bradley-Terry model for intra-study product ranking based on mean judges' predicted preference.
Number of subjects: 50
Study: 32300002

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and relaxation techniques administered by non-specialist providers, with six individual sessions and two to six booster sessions.
Number of subjects: 0
Study: 33320779

Group type: EXPERIMENTAL
Intervention: MIE (moderate-intensity exercise)
Number of subjects: 11
Study: 36114653

Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation (27 g per dose, thrice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isocaloric maltodextrin placebo
Number of subjects: 16
Study: 32993754

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Computerised Interactive Remediation of Cognition‐Training for Schizophrenia (CIRCuiTS)
Number of subjects: 100
Study: 35505387

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32304248

Group type: EXPERIMENTAL
Intervention: SCTG from tuberosity area (TG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: SCTG from lateral palate (CG)
Number of subjects: 29
Study: 36047276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed consent approaches
Number of subjects: 0
Study: 32149579

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 1,000 IU/day
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Single 200,000 IU injection (equivalent to 2,000 IU/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 32252707

Group type: EXPERIMENTAL
Intervention: Internet-delivered Acceptance and Commitment Therapy (IACT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Therapist guidance and deadlines for homework
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Adjusting treatment content and format based on participants' characteristics
Number of subjects: 11
Study: 36120427

Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 34501562

Group type: EXPERIMENTAL
Intervention: Brain Breaks videos for a period of four months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 70
Study: 32713367

Group type: EXPERIMENTAL
Intervention: ECT + low-frequency right prefrontal rTMS
Number of subjects: 35

Group type: COMPARATOR
Intervention: ECT + placebo
Number of subjects: 35
Study: 35353424

Group type: EXPERIMENTAL
Intervention: Gender-Rights Awareness Arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based skills training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline and endline assessments
Number of subjects: 0
Study: 33127467

Group type: EXPERIMENTAL
Intervention: Aquatic Activity (AA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 201
Study: 33369451

Group type: EXPERIMENTAL
Intervention: Protection motivation theory-based intervention
Number of subjects: 360
Study: 34896442

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (ER) strategy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) strategy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison of ER and SE strategies
Number of subjects: 35
Study: 34124926

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation bias (CBM‐I)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 135
Study: 34654028

Group type: EXPERIMENTAL
Intervention: HRV‐BF with 0.1‐Hz breathing
Number of subjects: 52

Group type: COMPARATOR
Intervention: HRV‐Sham‐BF
Number of subjects: 52
Study: 34148051

Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment Maneuver (RM) at 30 cmH₂O for 30 s
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham Maneuver (SM) at 5 cmH₂O for 30 s
Number of subjects: 59
Study: 32785986

Group type: EXPERIMENTAL
Intervention: Microneedling and 5-fluorouracil solution (group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intralesional 5-fluorouracil (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Microneedling (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 35152175

Group type: EXPERIMENTAL
Intervention: PreEMPT (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual Physiotherapy Care (UPC) (n = 8)
Number of subjects: 16
Study: 33568383

Group type: EXPERIMENTAL
Intervention: Roxadustat (70 mg oral, thrice-weekly)
Number of subjects: 2781

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Roxadustat (in patients with elevated high-sensitivity C-reactive protein)
Number of subjects: 2781

Group type: COMPARATOR
Intervention: Placebo (in patients with elevated high-sensitivity C-reactive protein)
Number of subjects: 2781

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 2781
Study: 32710452

Group type: EXPERIMENTAL
Intervention: Eye examination adherence (biennial guideline)
Number of subjects: 24832

Group type: EXPERIMENTAL
Intervention: Eye examination adherence (annual guideline)
Number of subjects: 24832

Group type: EXPERIMENTAL
Intervention: Factors associated with non-adherence
Number of subjects: 24832
Study: 35419530

Group type: EXPERIMENTAL
Intervention: Autologous adipose‐derived mesenchymal stem cells (AMSCs) delivered locally to the adventitia of the fistula.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 35710228

Group type: EXPERIMENTAL
Intervention: Exercise and photobiomodulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise and ultrasound
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise control group
Number of subjects: 36
Study: 34914617

Group type: EXPERIMENTAL
Intervention: Web-based program with health promotion officer (HPO) support
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Web-based program and implementation support strategies
Number of subjects: 22
Study: 36271847

Group type: EXPERIMENTAL
Intervention: 5A laboratory risk score model based on preoperative variables (older age, larger body mass index, lower platelet-neutrophile ratio, higher lymphocyte-monocyte ratio, higher D-dimer, lower fibrinogen, lower estimated glomerular filtration rate)
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Low risk patients
Number of subjects: 2397
Study: 35137458

Group type: EXPERIMENTAL
Intervention: GnRH (37.5 µg of Lecirelin)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: hCG (1000 I.U)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (1 mL of physiological saline solution)
Number of subjects: 39
Study: 34052828

Group type: EXPERIMENTAL
Intervention: Oral minocycline 100 mg bid for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 34981516

Group type: EXPERIMENTAL
Intervention: Krill oil (KO) - 7 capsules per day (1.27g n-3 PUFA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fish oil (FO) - 5 capsules per day (1.44g n-3 PUFA)
Number of subjects: 11
Study: 32997836

Group type: EXPERIMENTAL
Intervention: SCL (two-stage crown lengthening)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CCL (one-stage crown lengthening)
Number of subjects: 30
Study: 36351665

Group type: EXPERIMENTAL
Intervention: Air purifier with a high‐efficiency particulate air filter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air purifier with a placebo filter
Number of subjects: 30
Study: 33999936

Group type: EXPERIMENTAL
Intervention: Survey on demographics, clinical data, lifestyles, and cognitive status
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Comprehensive clinical examination including neurological and cognitive testing, MRI, and EEG
Number of subjects: 191
Study: 32598397

Group type: COMPARATOR
Intervention: Designated disadvantaged schools
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Irish adolescents (girls)
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Irish adolescents (boys)
Number of subjects: 1215

Group type: COMPARATOR
Intervention: European adolescents
Number of subjects: 1215
Study: 36136861

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 33166622

Group type: EXPERIMENTAL
Intervention: Diabetes education plus food vouchers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diabetes education plus stock boxes
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diabetes education plus combined food vouchers and stock boxes
Number of subjects: 300

Group type: COMPARATOR
Intervention: Diabetes education alone
Number of subjects: 300
Study: 34397606

Group type: EXPERIMENTAL
Intervention: Music listening on headphones
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 69
Study: 32331090

Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 561

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 561
Study: 36206208

Group type: EXPERIMENTAL
Intervention: Community-based occupational therapy intervention (COT-MHABI) over one year, 16 sessions on average.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline, 6 months, and 12 months assessments.
Number of subjects: 0
Study: 32946836

Group type: EXPERIMENTAL
Intervention: C difficile vaccine candidate (0.5 mL administered intramuscularly on days 0, 7, and 30)
Number of subjects: 9302

Group type: COMPARATOR
Intervention: Placebo vaccine (0.5 mL administered intramuscularly on days 0, 7, and 30)
Number of subjects: 9302

Group type: EXPERIMENTAL
Intervention: C difficile vaccine candidate
Number of subjects: 9302

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 9302
Study: 33970752

Group type: EXPERIMENTAL
Intervention: 5 mg of fast-release melatonin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 34999239

Group type: EXPERIMENTAL
Intervention: Single-dose ivermectin 1200 μg/kg for 5 days (arm C)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Single-dose ivermectin 600 μg/kg plus placebo for 5 days (arm B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (arm A)
Number of subjects: 93
Study: 32691207

Group type: EXPERIMENTAL
Intervention: Group A (surgery at 2 cm proximally to the pylorus)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group B (surgery at 6 cm proximally to the pylorus)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 150
Study: 32000208

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) intervention conducted in a hospital setting over 5 months.
Number of subjects: 71
Study: 36075243

Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg once daily for 28 days
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 406
Study: 32056346

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study: 35152573

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen acupuncture combined with carotid endarterectomy (CEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple carotid endarterectomy (CEA) with conventional treatment (aspirin and clopidogrel)
Number of subjects: 60
Study: 36038929

Group type: EXPERIMENTAL
Intervention: Targeted, theory-informed interventions (clinical leads, stakeholder meetings, train-the-trainer workshop, targeted educational package, audit/feedback)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Intervention hospitals
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1800
Study: 34555929

Group type: EXPERIMENTAL
Intervention: Self-care coaching
Number of subjects: 350

Group type: COMPARATOR
Intervention: Structured usual care
Number of subjects: 350
Study: 36308070

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: pegIFNβ‐1a
Number of subjects: 36
Study: 33646179

Group type: EXPERIMENTAL
Intervention: Cancers (melanoma, breast, prostate, endometrial, keratinocyte)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parkinson's disease (PD)
Number of subjects: 15
Study: 32835895

Group type: EXPERIMENTAL
Intervention: Therapeutic Outcomes By You application
Number of subjects: 15
Study: 35578536

Group type: EXPERIMENTAL
Intervention: HBOT plus venous intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Venous intervention alone
Number of subjects: 33
Study: 34456586

Group type: EXPERIMENTAL
Intervention: TPVB with 0.5% ropivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control with 0.9% saline
Number of subjects: 68
Study: 33059356

Group type: EXPERIMENTAL
Intervention: LSD 25 µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LSD 50 µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LSD 100 µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LSD 200 µg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg + LSD 200 µg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LSD (25-200 µg)
Number of subjects: 16
Study: 33188930

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propensity score methods, including g-computation and doubly robust estimators, specific details not available
Number of subjects: 0
Study: 34824100

Group type: EXPERIMENTAL
Intervention: Intervention group (hs-cTnT <5 ng/L at presentation)
Number of subjects: 10315

Group type: COMPARATOR
Intervention: Standard care group (hs-cTnT <99th centile at presentation)
Number of subjects: 10315
Study: 34267331

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 778

Group type: COMPARATOR
Intervention: PSA
Number of subjects: 778

Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 778

Group type: COMPARATOR
Intervention: ERSPC risk calculator (ERSPC-RC)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Various ML techniques (XGBoost, LightGBM, Catboost, Support vector machine (SVM), Logistic regression (LR))
Number of subjects: 778
Study: 33338271

Group type: EXPERIMENTAL
Intervention: Financial literacy intervention (Moving Ahead)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 449
Study: 35537533

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aflibercept 2 mg
Number of subjects: 0
Study: 32317794

Group type: EXPERIMENTAL
Intervention: Optometrists
Number of subjects: 129

Group type: COMPARATOR
Intervention: Ophthalmologists
Number of subjects: 129
Study: 32514076

Group type: EXPERIMENTAL
Intervention: LDL-c (low density lipoprotein cholesterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDL-c (high density lipoprotein cholesterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglycerides (TG)
Number of subjects: 0
Study: 35986699

Group type: EXPERIMENTAL
Intervention: brepocitinib 1% QD
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: brepocitinib 1% BID
Number of subjects: 292

Group type: COMPARATOR
Intervention: vehicle QD
Number of subjects: 292

Group type: COMPARATOR
Intervention: vehicle BID
Number of subjects: 292
Study: 32404117

Group type: EXPERIMENTAL
Intervention: Group P (FiO2 = 0.6, inhaling PGE1 0.1 μg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group P and Group L
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (FiO2 = 1.0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group P, Group L, and Group C
Number of subjects: 90
Study: 35475761

Group type: EXPERIMENTAL
Intervention: Peer Chatbot (free-choice group)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dialogical-Self Chatbot (free-choice group)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Expert Chatbot (younger participants < 40 years)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Institution Chatbot (younger participants < 40 years)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Peer Chatbot (older participants ≥ 40 years)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dialogical-Self Chatbot (older participants ≥ 40 years)
Number of subjects: 251

Group type: COMPARATOR
Intervention: No-choice group (general)
Number of subjects: 251
Study: 34520489

Group type: COMPARATOR
Intervention: Class 1 (low PIU risk)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Class 2 (high PIU risk)
Number of subjects: 1066
Study: 36282895

Group type: EXPERIMENTAL
Intervention: Compression garment (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No compression garment (n = 16)
Number of subjects: 32
Study: 33331622

Group type: EXPERIMENTAL
Intervention: Early in-bed cycling plus routine physiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Early routine physiotherapy alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study: 35086420

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 12
Study: 34494595

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 32465073

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Tacrolimus (TAC) and mycophenolate mofetil (MMF)
Number of subjects: 210
Study: 35659597

Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 fractions
Number of subjects: 50
Study: 33706522

Group type: EXPERIMENTAL
Intervention: Ferumoxytol nanoparticles (group 1, n=5)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ferumoxytol nanoparticles (group 2, n=8)
Number of subjects: 13
Study: 32951744

Group type: EXPERIMENTAL
Intervention: Abdominal massage for 15 minutes daily (Group A)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: PEG 20g daily (Group B)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: PEG 20g plus abdominal massage for 15 minutes daily (Group C)
Number of subjects: 143
Study: 35628840

Group type: EXPERIMENTAL
Intervention: Pre-emptive analgesic acetaminophen (15 mg/kg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 32555027

Group type: EXPERIMENTAL
Intervention: Land Walking (LW)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 34784897

Group type: EXPERIMENTAL
Intervention: PREPARED Trial intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 400
Study: 32235038

Group type: EXPERIMENTAL
Intervention: BIC/F/TAF
Number of subjects: 943

Group type: COMPARATOR
Intervention: DTG-based regimens
Number of subjects: 943
Study: 36206649

Group type: EXPERIMENTAL
Intervention: Self-compassion (SC) meditation intervention (3 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 71
Study: 35700207

Group type: EXPERIMENTAL
Intervention: Bundled devices (BDs)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Standard devices (SDs)
Number of subjects: 989
Study: 33831899

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg bolus over 10 min followed by continuous infusion of 100 μg/kg/min)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study: 34980867

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bempedoic acid and ezetimibe combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study: 33176703

Group type: EXPERIMENTAL
Intervention: Group-based multicomponent high intensity exercise program led by a physiotherapist twice a week for 4 months.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (home-based exercise program with encouragement to exercise according to WHO recommendations).
Number of subjects: 89
Study: 36564950

Group type: EXPERIMENTAL
Intervention: Combined SST and LLLT
Number of subjects: 42

Group type: COMPARATOR
Intervention: LLLT
Number of subjects: 42

Group type: COMPARATOR
Intervention: SST
Number of subjects: 42
Study: 34480880

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0